2018 - 2022 Establishment of new therapy targeting immune response and angiogenesis regulator vasohibin in prostate cancer
2018 - 2019 前立腺癌におけるバソヒビンを標的とした新規治療戦略の確立
2016 - 2018 A new strategy for the treatment of prostate cancer by targeting vasohibin family
2016 - 2017 前立腺癌におけるVASH1、VASH2の発現とその機能解析
2014 - 2016 Investigation of the expression of vasohibin regulated by the epigenetic mechanism in urothelial carcinoma
2015 - 2016 前立腺癌におけるVASH1、VASH2の発現とその機能解析
2014 - 2015 前立腺癌におけるVASH1、VASH2の発現とその機能解析
2013 - 2014 尿路上皮癌におけるVASH1, VASH2の発現とその機能解析
2012 - 2013 尿路上皮癌におけるVASH1, VASH2の発現とその機能解析
2011 - 2012 尿路上皮癌におけるVASH1, VASH2の発現とその機能解析
Show all
Papers (38):
Shinnosuke Fujiwara, Masaru Ishida, Eri Arai, Yuto Baba, Tadatsugu Anno, Hiroaki Kobayashi, Yasumasa Miyazaki. Isolated recurrence of prostate cancer to the anterior urethra 5 years after radiation therapy. IJU case reports. 2022. 5. 1. 58-61
Kyohei Hakozaki, Eiji Kikuchi, Koichiro Ogihara, Keisuke Shigeta, Takayuki Abe, Yasumasa Miyazaki, Gou Kaneko, Takahiro Maeda, Shunsuke Yoshimine, Kunimitsu Kanai, et al. Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. Japanese journal of clinical oncology. 2021. 51. 2. 287-295
Naoya Niwa, Nobuyuki Tanaka, Hiroshi Hongo, Yasumasa Miyazaki, Kimiharu Takamatsu, Ryuichi Mizuno, Eiji Kikuchi, Shuji Mikami, Takeo Kosaka, Mototsugu Oya. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory investigation; a journal of technical methods and pathology. 2019. 99. 11. 1702-1713
Go Kaneko, Suguru Shirotake, Koshiro Nishimoto, Yasumasa Miyazaki, Keiichi Ito, Yujiro Ito, Masayuki Hagiwara, Kent Kanao, Ken Nakagawa, Tetsuo Momma, et al. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. Japanese journal of clinical oncology. 2019. 49. 8. 780-785
Keiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, Yota Yasumizu, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, et al. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Japanese journal of clinical oncology. 2019. 49. 1. 69-76
THE ANALYSIS OF EXPRESSION AND MOLECULAR MECHANISM FOR VASOHIBIN-2 IN PROSTATE CANCER
(American Urological Association (AUA) 2018 Annual Meeting 2018)
EFFECTS OF SEX HORMONES ON CELL PROLIFERATION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
(American Urological Association (AUA) 2017 Annual Meeting 2017)
A NEW STRATEGY FOR THE TREATMENT OF PROSTATE CANCER BY TARGETING VASOHIBIN-2
(American Urological Association (AUA) 2016 Annual Meeting 2016)
IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY
(2016)
THE PROGNOSTIC IMPACT OF HISTONE H3K27 TRIMETHYLATION REGULATED BY EZH2 IN PATIENTS WITH UPPER URINARY TRACT UROTHELIAL CARCINOMA
(American Urological Association (AUA) 2015 Annual Meeting 2015)
The Japan Endocrine Society
, Japanese Cancer Association
, Japan Society of Clinical Oncology
, Japanese Society of Endourology
, The Japanese Urological Association